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To the Editor: It is currently accepted that metformin inhibits
complex I of the respiratory chain, altering the ratio of AMP or
ADP to ATP and subsequently inhibiting gluconeogenesis [1,
2]. The original insulin clamp studies of the 1990s investigating
the effect of metformin on glucose metabolism in obese and
lean individuals with type 2 diabetes support this mechanism of
action [3], demonstrating a reduction in endogenous glucose
production (EGP) following metformin treatment. However,
an increasing number of alternative pathways of metformin
action have been proposed, including 5′AMP-activated protein
kinase (AMPK)-dependent and -independent effects, as well as
gastrointestinal mechanisms of action [4, 5].
It is, therefore, with great interest that we read the article
recently published in Diabetologia entitled ‘Metformin
increases endogenous glucose production in non-diabetic
individuals and individuals with recent-onset type 2 diabetes’
[6]. In the article, using studies of whole-body glucose metab-
olism, including non-steady state glucose tracer kinetics and
hyperinsulinaemic–euglycaemic clamping, Gormsen et al
report that metformin treatment is associated with an increase
in the glucose rate of disappearance (Rd), glucagon levels and
EGP both in healthy control individuals and in individuals
with recent-onset type 2 diabetes with good glycaemic
control. These changes were absent in a placebo-treated
group.
In this letter we present data from our recent study of non-
diabetic individuals, which aimed to investigate the effect of
metformin on glucose kinetics. Our findings corroborate the
findings of Gormsen et al, adding to the pool of evidence
indicating that the mechanism of action of metformin may
be extra-hepatic.
Our study was conducted in the Clinical Research Centre at
Ninewells Hospital, Dundee, between September 2016 and
August 2017. It was co-sponsored by the University of
Dundee and NHS Tayside, and ethical approval was granted
by the East of Scotland Research Ethics Committee. The study
was conducted in accordance with the Good Clinical Practice
guidelines and the Declaration of Helsinki. The study was
registered on the public database clinicaltrials.gov (identifier
NCT02733679). Formal written informed consent was
obtained from each individual prior to inclusion. Here we
report the data from the non-diabetic controls.
In this non-randomised, non-blinded, open-label crossover
study we treated non-diabetic individuals with two commonly
used diabetes drugs, namely, metformin and pioglitazone. The
time in study was 17 weeks, consisting of two 8 week treat-
ment periods separated by 1 week washout. During treatment
period one, participants were treated with metformin, titrated
to a maximum of 1000 mg twice daily. During treatment peri-
od two, participants were treated with pioglitazone, titrated to
30 mg once daily. Each participant had three study visits:
baseline, post-metformin and post-pioglitazone. Each visit
included a dual-tracer mixed-meal test (MMT), to assess
glucose kinetics in the fasted and non-steady state.
In brief, participants received a standardised meal the
evening before the MMT. They were fasted from midnight
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and attended the Clinical Research Centre at 08:00 hours. After
taking a baseline blood sample from each participant, a primed
(6 mg/kg infused for 1 min) continuous (0.06 mg kg−1 min−1
for 120 min) infusion of [6,6-2H2]glucose (Euriso-Top, Saint-
Aubin, France) was administered over an initial 2 h period,
from −120 to 0 min, to reach steady state. Once in steady state,
a liquid mixed meal labelled with [U-13C]glucose (1.7 g added
to 71.9 g glucose drink, 220 ml total volume; Cambridge
Isotope Laboratories, Andover, MA, USA), along with liquid
paracetamol (1 g in 20 ml), was ingested. Over the following
6 h, a variable infusion of [6,6-2H2]glucose was administered,
with the rate mimicking the expected EGP post meal. Blood
samples were taken at 21 time points over the 8 h period.
Samples were analysed for glucose at each time point, using
gas chromatography–mass spectrometry to differentiate endog-
enous from labelled glucose (Agilent 7890A Gas
Chromatographer and Agilent 5975 Mass Spectrometry detec-
tor, Agilent Technologies, Wokingham, UK). Insulin (ELISA
80-INSHU-E01.1, Alpco, Salem, MA, USA), glucagon
(radioimmunoassay RIA; GL-32 K, Millipore, UK) and
paracetamol level (enzymatic bichromatic endpoint technique
on a Dimension VISTA 1500, Siemens; used as a measure of
gastric emptying) were also measured. Glucose kinetics were
modelled using the circulatory model [7], to assess EGP,
glucose clearance and the rate of appearance of oral glucose.
Statistical analyses were performed using R studio (rstudio.
com; R version 3.1.0, R Foundation for Statistical
Computing, Vienna, Austria). Variables are reported as fasting
or meal mean (whereby the average increment was calculated
by dividing the AUC of the variable in question by the duration
of the meal test). Data were tested for normality using Shapiro–
Wilk test. Normally distributed data are presented as mean ±
SEM, and compared within group using the paired t test. Non-
normally distributed data are presented as median with inter-
quartile range (IQR) and compared using theMann–WhitneyU
test. Statistical significance was defined as p < 0.05.
In total, 18 non-diabetic individuals were recruited. Of
these, 15 completed the study, six of whom (40%) were
female. The mean age was 22.4 years, BMI was 24.0 kg/m2,
and HbA1c was 33 mmol/mol (5.2%). One individual
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Fig. 1 Fasting EGP (a); meal mean EGP (b); fasting glucose clearance (c) and meal mean glucose clearance (d) at all visits. Data are median (IQR) of all
participants (n=15) in each cohort
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withdrew from the study due to metformin side effects, and
two participants withdrew due to vomiting during the MMT.
Metformin did not affect gastric emptying, nor did it impact
upon the rate of appearance of oral glucose. Fasting glucose and
insulin concentrations were unchanged from baseline, following
metformin treatment. However, there was an increase in fasting
glucose clearance compared with baseline (baseline 2.7 [IQR
2.3–2.8] vs post metformin 3.0 [IQR 2.7–3.4] ml min−1 kg−1,
p< 0.001). This was associated with an increase in the mean
glucagon during the MMT (baseline 54.5 [IQR 35.8–71.0] vs
post metformin 58.4 [IQR 42.3–78.4] pg/ml, p = 0.007).
Fasting glucagon was elevated from baseline, though did not
reach significance (baseline 54.8 [IQR 42.0–70.5] vs post
metformin 65.2 [IQR 36.9–83.4] pg/ml, p = 0.28).
During fasting, participants are in steady state, where EGP is
equal to Rd. Therefore, as there is an increase in glucose clear-
ance, metformin treatment also resulted in an increase in EGP
under fasting conditions (baseline 10.9 [IQR 10.1–12.4] vs post
metformin 13.8 [11.7–15.0] μmol min−1 kg−1, p < 0.001) (Fig.
1). Mean EGP during the MMTwas elevated but did not reach
significance (baseline 5.2 [IQR 4.8–6.5] vs post metformin 6.1
[IQR 4.4–7.0] μmol min−1 kg−1, p = 0.28). Pioglitazone had no
impact on glucose clearance, EGP or glucagon.
This data from dual-tracer MMTs has provided some inter-
esting insight into the mechanism of action of metformin.
Metformin treatment was associated with increased fasting
glucose clearance, which has been previously reported in
clamp data [3, 8–10]. The increase in clearance could repre-
sent increased glucose uptake by the intestine, which has
recently been postulated as a ‘glucose sink’ [11, 12].
Our non-diabetic group showed a metformin-related coun-
ter-regulatory increase in their mean glucagon level, and
perhaps this occurs to prevent hypoglycaemia in the context
of increased glucose clearance in these normoglycaemic indi-
viduals. In keeping with this, they show an increase in their
fasting EGP, which may be due to glucagon-induced glyco-
genolysis or gluconeogenesis. This finding is consistent with
the data presented by Gormsen et al [6].
The metformin-associated increase in EGP demonstrates
that the mechanism of action of metformin is not entirely
explained by a reduction in hepatic gluconeogenesis.
However, these metformin response pathways are not neces-
sarily mutually exclusive. In the context of marked
hyperglycaemia, such as in individuals with poorly controlled
diabetes, the metformin-associated increase in glucose clear-
ance may not be sufficient to induce hypoglycaemia or stimu-
late counter-regulatory mechanisms, such as glucagon. In this
setting, when baseline hepatic glucose output is high, the
hepatic effects of metformin to reduce gluconeogenesis may
dominate. A previous clamp study on the effect of metformin
effect on glucose metabolism recruited individuals with poorly
controlled diabetes (baseline HbA1c 84 mmol/mol [9.8%]) [3].
These study participants were hyperglycaemic and had
elevated EGP. It is interesting that metformin augmented
non-insulin mediated glucose uptake in both our study and that
by Gormsen et al, but this would have a small impact and, in
the context of hyperglycaemia, would be unlikely to trigger a
counter-regulatory response. However, in the healthy individ-
ual with normoglycaemia, increased glucose clearance may
put the individual at risk hypoglycaemia, thereby stimulating
glucagon secretion. The inhibitory effect of metformin on
gluconeogenesis would be outweighed by the stimulatory
effects of glucagon on glycogenolysis and gluconeogenesis.
In summary, the effect of metformin on glucose metabo-
lism appears to be dependent on the glycaemic state of the
individual. Using an alternative study design to that used by
Gormsen et al, our data lends support to the suggestion that
metformin increases glucose clearance, which results in an
increase in EGP in the healthy individual, via counter-
regulatory hormones, which is in contrast to the reduction in
EGP seen in the individual with poorly controlled diabetes.
Acknowledgements The authors would like to thankC.Glen (PA to E. R.
Pearson, University of Dundee, Dundee, UK) for logistical management
of the participants’ study visits. They would also like to thank L. Cabrelli
and H. Loftus (research nurses, CRC, University of Dundee) for
conducting study visits and general assistance in running the study, and
G. Kiddie (lab manager) and L. King (lab technician) (both CRC,
University of Dundee) for initial processing and organising sample stor-
age and transfers.
Data availability The datasets generated during and / or analysed during
the current study are available from the corresponding author on reason-
able request.
Funding This work was funded by the Wellcome Trust New Investigator
Award (102820/Z/13/Z), awarded to ERP.
Duality of interest The authors declare there is no duality of interest
associated with this manuscript.
Contribution statement LJM designed and led the study, performed
statistical analysis, and drafted and revised the article. LC and NJ
performed mass spec analysis and reviewed the manuscript. AM
performed the glucose kinetics modelling and reviewed the manuscript.
AMU contributed to study design, mass spec analysis and reviewed the
manuscript. ERP was chief investigator of the study, contributed to study
conception and design, contributed to and reviewed the manuscript and is
the guarantor of this work. All authors reviewed and approved the final
version for publication.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Hunter RW, Hughey CC, Lantier L et al (2018) Metformin reduces
liver glucose production by inhibition of fructose-1-6-
Diabetologia
bisphosphatase. Nat Med 24(9):1395–1406. https://doi.org/10.
1038/s41591-018-0159-7
2. Miller RA, Birnbaum MJ (2010) An energetic tale of AMPK-
independent effects of metformin. J Clin Invest 120(7):2267–
2270. https://doi.org/10.1172/JCI43661
3. DeFonzo RA, Barzilai NIR, Simonson DC (1991) Mechanism of
metformin action in obese and lean noninsulin-dependent diabetic
subjects. J Clin Endocrinol Metab 73(6):1294–1301. https://doi.
org/10.1210/jcem-73-6-1294
4. McCreight LJ, Bailey CJ, Pearson ER (2016) Metformin and the
gastrointestinal tract. Diabetologia 59(3):426–435. https://doi.org/
10.1007/s00125-015-3844-9
5. Rena G, Hardie DG, Pearson ER (2017) The mechanisms of action
of metformin. Diabetologia 60(9):1577–1585. https://doi.org/10.
1007/s00125-017-4342-z
6. Gormsen LC, Søndergaard E, Christensen NL, Brøsen K, Jessen N,
Nielsen S (2019) Metformin increases endogenous glucose produc-
tion in non-diabetic individuals and individuals with recent-onset
type 2 diabetes. Diabetologia 62(7):1251–1256. https://doi.org/10.
1007/s00125-019-4872-7
7. Mari A, Stojanovska L, Proietto J, Thorburn AW (2003) A circula-
tory model for calculating non-steady-state glucose fluxes.
Validation and comparison with compartmental models. Comput
Methods Prog Biomed 71(3):269–281. https://doi.org/10.1016/
s0169-2607(02)00097-4
8. McIntyre HD, Ma A, Bird DM, Paterson CA, Ravenscroft PJ,
Cameron DP (1991) Metformin increases insulin sensitivity and
basal glucose clearance in type 2 (non-insulin dependent) diabetes
mellitus. Aust NZ J Med 21(5):714–719. https://doi.org/10.1111/j.
1445-5994.1991.tb01375.x
9. Hother-Nielsen O, Schmitz O, Andersen PH, Beck-Nielsen H,
Pedersen O (1989) Metformin improves peripheral but not hepatic
insulin action in obese patients with type II diabetes. Acta
Endocrinol 120(3):257–265. https://doi.org/10.1530/acta.0.
1200257
10. Chiswick CA, Reynolds RM, Denison FC et al Does metformin
reduce excess birthweight in offspring of obese pregnant women?
A randomised controlled trial of efficacy, exploration of mecha-
nisms and evaluation of other pregnancy complications. Efficacy
and Mechanism Evaluation, no. 3.7. NIHR Journals Library,
Southampton
11. Zarrinpar A, Chaix A, Xu ZZ et al (2018) Antibiotic-induced
microbiome depletion alters metabolic homeostasis by affecting
gut signaling and colonic metabolism. Nat Commun 9(1):2872.
https://doi.org/10.1038/s41467-018-05336-9
12. Koffert JP, Mikkola K, Virtanen KA et al (2017) Metformin treat-
ment significantly enhances intestinal glucose uptake in patients
with type 2 diabetes: results from a randomized clinical trial.
Diabetes Res Clin Pract 131:208–216. https://doi.org/10.1016/j.
diabres.2017.07.015
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Diabetologia
